US › Healthcare

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)

US · Healthcare · Biotechnology

$1.86-11.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.8M

EPS

$-2.75

EPS estimate

$0.65

EPS came in at -2.75 against a street estimate of 0.65 — a miss of 523.1%.

Key statistics

Market cap

$4.9M

Forward P/E

0.0

P/B

1.27

Book value

$2.00

EPS (TTM)

$-2.88

52-week high

$9.82

52-week low

$0.58

50-day MA

$2.36

200-day MA

$9.59

Analyst view

with an average price target of $12.00.

Shareholding

Insiders

37.13%

Institutions

4.19%

Largest institutional holders

Fund	Stake
Ronald Blue Trust, Inc.	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lakewood-Amedex Biotherapeutics Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.